PEGS China: Protein & Antibody Engineering and Development Summit

Venue: Shanghai Marriott Hotel Pudong East

Location: Shanghai, China

Event Date/Time: Apr 01, 2014 End Date/Time: Apr 03, 2014
Early Registration Date: Feb 28, 2014
Report as Spam


CHI is excited to announce the launch of "PEGS China". Spurred by the growth in the biopharmaceutical sector in Asia and the demand by our participants and exhibitors to bring higher quality, established and credible conferences to this region, CHI will launch its first Asia PEGS Summit in China in April 2014. The event will focus on topics of greater relevance and interest to the China/Asia biopharmaceutical industry, including protein and antibody engineering, protein expression, analytical techniques and CMC strategies.   "PEGS Summit" has grown in leaps and bounds driven by the growth in biologics worldwide. Attracting over 1600 participants at this year's 9th Annual PEGS Summit in Boston, and record attendance expected at the upcoming PEGS Europe event being held in Lisbon, "PEGS" is CHI's flagship biologics event, and considered the industry leading event.


15 Xinjinqiao Road

Conference Speakers

Confirmed speakers include:

  • Frank Bernhard, Ph.D., Lab Head, Institute of Biophysical Chemistry, Goethe University Frankfurt, Germany
  • Chris Chen, Ph.D., SVP and Chief Technology Officer, Biologics Services, Wuxi Apptec
  • Yan Chen, M.D., Ph.D., Senior Vice President, Research, X-BODY Biosciences, USA
  • Ho Cho, Chief Technology Officer, Ambrx
  • Danny Chou, PharmD, Ph.D., MBA, Senior Research Scientist, Biologics, Gilead Sciences, USA
  • Partha Chowdhury, Ph.D., Principal Scientist, Antibody Discovery and Protein Engineering, MedImmune, LLC., USA
  • Maria J. de Jesus, Ph.D., Co-Founder & COO, ExcellGene SA, Switzerland
  • Davide de Lucrezia, Ph.D., CEO, Explora Biotech SRL, Italy
  • Dimiter Dimitrov, Ph.D., Senior Investigator, Center for Cancer Research, NCI, NIH
  • Changlin Dou, Ph.D., CTO, Luye Biologics, China
  • Daotian Fu, Ph.D., Executive Vice President, Livzon MabPharm, Inc., China
  • Ning Gao, Senior Scientist, AstraZeneca Pharmaceuticals, USA
  • Matthias Germer, Ph.D., Senior Director, Preclinical Research, Biotest AG, Germany
  • Tariq Ghayur, Research Fellow, Antibody Engineering, Abbvie, USA
  • Rui Gong, Ph.D., Professor, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, China
  • Ingo Gorr, Ph.D., Principal Scientist, Cell Culture Research, Large Molecule Research, Roche Diagnostics GmbH, Germany
  • Ulf Grawunder, Ph.D. CEO, NBE-Therapeutics, enzyme assisted ADC conjugation
  • Vaughn B . Himes, Ph.D., Executive Vice President, Process Sciences and Technical Operations, Seattle Genetics, USA
  • Ian Hunt, Ph.D., Head of Protein Sciences, Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, USA
  • Andrea Ji, Ph.D., Senior Scientist, Late Stage Pharmaceutical Development, Genentech, Inc.
  • Shan Jiang, Ph.D., Director, Formulation and Fill/Finish, Seattle Genetics, Inc., USA
  • Weidong Jiang, Ph.D., Chief Scientific Officer & VP, Henlius Biopharmaceuticals, Inc., USA
  • Feng Tian, Ph.D., Head of Ambrx China
  • Anand Khedkar, M. Tech, Chief Scientific Manager, R&D, Biocon Research Limited, India
  • Dan Klassen, Founder, Klassen Consulting LLC & Associates
  • Michael Lee, Vice President, Operations, DesigneRx Pharmaceuticals, Inc.
  • Mark Perkins, Customer Technical Solutions Manager, Novozymes Biopharma UK Ltd., United Kingdom
  • H Fai Poon, Ph.D., Director, Cell Culture, Hisun Pharmaceuticals, China
  • Xueming Qian, Ph.D., Chairman and CEO, R&D, Mabspace Biosciences
  • Arvind Rajpal, Ph.D., Vice President, Protein Engineering, Rinat
  • Sai Reddy, Ph.D., Assistant Professor, Department of Biosystems Science and Engineering, ETH Zurich, Switzerland
  • Mike Romanos, Ph.D., Chief Executive Officer, Crescendo Biologics, United Kingdom
  • Johannes Salzbrunn, Head of Downstream Pilot, Process Science Microbials, Boehringer-Ingelheim RCV GmbH & Co. KG, Austria
  • Li Shi, Ph.D., Chief Executive Officer, Shanghai Zerun Pharmaceuticals, China
  • Shuangping Shi, Ph.D, Group Lead (Cell Line Development), BioProcess Development, Merck & Co., USA
  • Daniel J. Sikkema, Ph.D., Executive Director, Biopharm R&D, Head of Clinical immunology, GlaxoSmithKline, USA
  • Michela Silacci, Director Discovery Research, Covagen AG, Switzerland
  • Stefanie Urlinger, Ph.D., Director R&D, Discovery Alliances Technologies, MorphoSys AG, Germany
  • Prof. Florian Wurm, EPFL, mammalian cell expression engineering
  • Xing Wang, Ph.D., President, Array Bridge
  • Harald Wegele, Ph.D., Director, Development Analytics, Pharma Biotech Development, Roche Diagnostics GmbH, Germany
  • Scott M. Wheelwright, Ph.D., Principal Consultant, Complya Asia Co., Ltd., China
  • Florian M. Wurm, Ph.D, Professor of Biotechnology, Swiss Federal Institute of Technology, Switzerland
  • Jingyi Xiang, Ph.D., Head of Bioanalytics, Eureka Therapeutics, Inc., USA
  • Ting Xu, Ph.D., Chief Executive Officer, AlphaMab Co., Ltd., China
  • Weiming Xu, Chief Executives Officer, Molecular Biology, London Biotech Ltd., United Kingdom
  • Yiming Yang, Ph.D., Senior Scientist, Shire Human Genetic Therapies, USA
  • Jin-San Yoo, President, PharmAbcine, Korea
  • Lei Zheng, M.D., Ph.D., Assistant Professor, Oncology, John Hopkins University School of Medicine, USA
  • Xiaoyang Zheng, Ph.D., Staff Scientist II, Analytical Development, Genzyme Corporation, a Sanofi Company
  • Marie M. Zhu, Ph.D., Director of Process Sciences, Technical Operations, Agensys Inc., an Affiliate of Astellas Pharma Inc.
  • Eugene Zhukovsky, Ph.D., Chief Scientific Officer, Affimed Therapeutics AG, Germany¬†

Exhibits included

Current exhibitors include:

  • Fluid Imaging Technologies
  • Malvern Instruments
  • MaxCyte, Inc.